Effect of Xiaoer Zhixiaoling Tablets on Airway Reactivity of Cough Variant Asthma in Attack Period

GUO Jie; LIU Jie-yun; WU Ya-jun; DONG Jin-lei

doi:10.13422/j.cnki.syfjx.2017180204

您当前的位置：

首页 >

文章列表页 >

Effect of Xiaoer Zhixiaoling Tablets on Airway Reactivity of Cough Variant Asthma in Attack Period

更新时间：2024-01-04

- Effect of Xiaoer Zhixiaoling Tablets on Airway Reactivity of Cough Variant Asthma in Attack Period
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 18, Pages: 204-209(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017180204
  CLC： R272
- Published：2017
- 稿件说明：
移动端阅览
GUO Jie, LIU Jie-yun, WU Ya-jun, et al. Effect of Xiaoer Zhixiaoling Tablets on Airway Reactivity of Cough Variant Asthma in Attack Period[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(18): 204-209.
DOI：

GUO Jie, LIU Jie-yun, WU Ya-jun, et al. Effect of Xiaoer Zhixiaoling Tablets on Airway Reactivity of Cough Variant Asthma in Attack Period[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(18): 204-209. DOI： 10.13422/j.cnki.syfjx.2017180204.

摘要

目的：评价小儿治哮灵片对发作期咳嗽变异性哮喘（CVA）的临床疗效及对气道反应性和慢性炎症反应的影响。方法：将170例发作期CVA患儿，采用区组随机按数字表法分为对照组和观察组各85例。两组患儿均采用布地奈德气雾剂+孟鲁司特钠咀嚼片进行治疗，观察组加服小儿治哮灵片。两组疗程均为4周，并进行16周的随访。进行日间咳嗽、夜间咳嗽情况和咳嗽视觉模拟（VAS）评分；进行治疗前后莱塞斯特咳嗽问卷（LCQ）评分和中医证候评分；记录咳嗽缓解时间和16周内的复发情况；进行治疗前后气道反应检测；进行治疗前后白细胞介素-4（IL-4），IL-5，IL-13，嗜酸性粒细胞（EOS）和血清免疫球蛋白（IgE）检测。结果：观察组中医疗效总有效率为93.59%，高于对照组的81.33%（χ2=5.281，P<0.05）；治疗后观察组患儿日间咳嗽、夜间咳嗽、咳嗽总积分及咳嗽VAS评分均低于对照组（P<0.01）；观察组平均咳嗽缓解时间短于对照组（P<0.01）；在16周的随访期中，观察组复发率为39.74%，低于对照组的61.33%（χ2=5.281，P<0.05），观察组平均复发次数低于对照组（P<0.01）；治疗后观察组LCQ量表2个维度评分和总分均高于对照组（P<0.01）；观察组患儿血清IL-4，IL-5，IL-13，总IgE和EOS水平均低于对照组（P<0.01）；观察组患儿最小诱发累积剂量（Dmin）和PD35水平均高于对照组（P<0.01）。结论：小儿治哮灵片治疗发作期咳嗽变异性哮喘，能进一步的缓解咳嗽等临床症状，提高患者的生活质量，并能降低复发频率，其作用机制可能是通过减轻气道炎症反应、降低气道高反应性来实现的。

Abstract

Objective: To evaluated the clinical efficacy of Xiaoer Zhixiaoling tablets on cough variant asthma (CVA) in attack period and its effect on airway reactivity and chronic inflammatory response.Method: One hundred and seventy patients with CVA in attack period were divided into control group and observation group by random number table

with 85 cases in each group. Patients in control group got budesonide aerosol and montelukast sodium chewable tablets. Patients in observation group were also given Xiaoer Zhixiaoling tablets. A course of treatment was four weeks. And a 16-week following-up visit were made. Daytime

nighttime coughing and cough visual analogue scale (VAS) were scored. Before and after treatment

Leicester cough questionnaire (LCQ) and symptoms of traditional Chinese medicine (TCM) were scored. Recurrence during the 16 weeks and cough remission time were recorded. Before and after treatment

airway reaction and levels of interleukin-4 (IL-4)

IL-5

IL-13

eosinophils (EOS) and serum IgE were also detected.Result: The total effect rate in observation group was 93.59%

which was higher than 81.33% in control group (χ2=5.281

P<0.05). After treatment

daytime cough

night cough and total cough scores and cough VAS were all lower than those in control group (P<0.01). Mean cough remission time in observation group was shorter than that in control group (P<0.01). During the 16-week follow-up visit

the recurrence rate in observation group was 39.74%

which was lower than 61.33% in control group (χ2=5.281

P<0.05)

and the average frequency were lower than those in control group (P<0.01). The two dimension scores of LCQ and the total score were higher than those in control group (P<0.01). And levels of IL-4

IL-5

IL-13

IgE and EOS were lower than those in control group (P<0.01). The minimum induced cumulative dose and PD35 were higher than those in control group (P<0.01).Conclusion: Xiaoer Zhixiaoling tablets have a certain effect on in treating cough variant asthma (CVA)

and can relieve symptom

improve the quality of life of the patients

and reduce recurrence frequency. Its mechanism of action may be realized by reducing airway inflammation and airway hyper-responsiveness.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy on Erchentang Combined with Sanzi Yangqintang in Treatment of Cough Variant Asthma in Children with Phlegm Evil Accumulation Lung Syndrome

Kangmin Zhike Mixture by Oral Taking or Aerosol Inhalation on Children with Cough Variant Asthma

Yijingtang Reduces Ovarian Inflammatory Responses in Rat Model of Diminished Ovarian Reserve via TLR4/MyD88/NF-κB Signaling Pathway

Mechanism of Shengmai Injection Against Cerebral Ischemia Based on Proteomics

Research Advances on Anti-inflammatory and Anti-oxidation Effect of Medicinal and Edible Herbs Liver-protecting Chinese Medicine

Related Author

Jun WAN

Zhou YU

Meng-tian SUN

Xiang-zheng YANG

YANG Yu

CHEN Yu-wen

CHEN Miao-ping

WANG Shi-qun

Related Institution

Shenzhen Hospital of Beijing University of Chinese Medicine（Longgang）

The First Clinical Medical School of Anhui University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

School of Pharmacy，Zunyi Medical University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰